Pulmonary percutaneous valve implantation in large native right ventricular outflow tract with 32 mm Myval transcatheter heart valve

Catheter Cardiovasc Interv. 2022 Jan 1;99(1):E38-E42. doi: 10.1002/ccd.29985. Epub 2021 Oct 21.

Abstract

Pulmonary percutaneous valve implantation (PPVI) is feasible with satisfactory mid-term results in patients with native right ventricular outflow tract (RVOT) and has been increasingly used instead of surgically implantable pulmonary valves. Creating a stable landing zone with a diameter less than the largest commercially available valve (previously available 29 mm and currently available 32 mm) is crucial for technical success of the procedure, limiting the number of suitable candidates for PPVI. We report the case of PPVI with a 32 mm Myval transcatheter heart valve in a patient with a large native RVOT (pre-stented with AndraStent XXL mounted on a 35 × 60 mm valve balloon catheter) lesion who had Tetralogy of Fallot surgically corrected. The post-procedural outcomes of this case were satisfactory with no complications reported during the hospital stay.

Keywords: native outflow tract; percutaneous pulmonary valve implantation; pulmonary valve.

Publication types

  • Case Reports

MeSH terms

  • Cardiac Catheterization
  • Heart Valve Prosthesis Implantation* / adverse effects
  • Heart Valve Prosthesis*
  • Humans
  • Prosthesis Design
  • Pulmonary Valve Insufficiency* / diagnostic imaging
  • Pulmonary Valve Insufficiency* / etiology
  • Pulmonary Valve Insufficiency* / surgery
  • Pulmonary Valve* / diagnostic imaging
  • Pulmonary Valve* / surgery
  • Treatment Outcome
  • Ventricular Outflow Obstruction* / diagnostic imaging
  • Ventricular Outflow Obstruction* / etiology
  • Ventricular Outflow Obstruction* / surgery